Hematologic Malignancies
Servier Affaires Medicales is involved in clinical research for isocitrate dehydrogenase 1 mutation-positive acute myeloid leukemia, with a focus on adult patients who are not candidates for intensive induction chemotherapy.
- IDH1m AML
- Adult leukemia
- Non-intensive treatment settings
The sponsor’s research activity in this area centers on targeted oncology care for genetically defined blood cancers.
Biliary Tract Cancer
The sponsor also supports studies in cholangiocarcinoma, particularly in patients with locally advanced or metastatic disease who have received prior treatment.
- Locally advanced cholangiocarcinoma
- Metastatic cholangiocarcinoma
- Pretreated disease
This reflects a therapeutic interest in difficult-to-treat biliary tract cancers with limited options after earlier therapy.
Targeted Oncology
Across its funded trials, the sponsor’s clinical research landscape is centered on ivosidenib-based treatment strategies in cancers driven by IDH1 mutation biology.
- IDH1-targeted therapy
- Precision oncology
- Mutation-directed cancer care
Its research activity spans both hematologic and solid tumor oncology within a molecularly defined therapeutic domain.
Supportive Clinical Access
The sponsor is active in studies that extend access to treatment for patients with advanced cancer across multiple international research sites.
- International oncology research
- Multicountry trial network
- Advanced cancer care
Its portfolio includes research settings relevant to both newly diagnosed AML and advanced cholangiocarcinoma.
